BRCA1 and breast carcinoma: Since breast cancers with defective BRCA1 and HR pathway are sensitive to DNA damage-inducing anticancer drugs such as PARPi, our study provides a novel target for the treatment of breast cancer, as well as the development of anticancer drugs.